AI-EngineeredUniversal Vaccine Offers Broad Protection Against Future Viral Threats

A consortium of British scientists, headed by researchers from the Universities of Cambridge and Southampton, has created the first vaccine whose design was completed by artificial intelligence and is now undergoing human testing.

According to Professor Saul Faust of the University of Southampton, who led the trial, viruses such as influenza, coronaviruses, and those in the Ebola family continuously evolve, often rendering vaccine matches incomplete; the conventional reactive approach struggles to keep pace.

In recent years, betacoronaviruses have triggered several outbreaks, the most notable being the COVID‑19 pandemic; ongoing viral circulation drives mutation and the emergence of new variants.

Acknowledging the necessity for vaccines that confer broad, enduring protection against both present and future viral mutations, the researchers have engineered a novel immunogen that can shield against a wide spectrum of viruses, including Ebola and coronaviruses, even as they evolve.

Heeney further noted that this class of universal vaccines may eventually guard against pathogens that have yet to emerge.

How did they use AI?

To develop the vaccine, the team employed an AI‑generated active ingredient called a super‑antigen. This synthetic protein replicates common structural elements found across several coronaviruses, thereby eliciting an immune response capable of combating a broad range of viruses sharing those characteristics.

The researchers compiled comprehensive genetic sequence data for bat‑derived sarbecoviruses collected globally, feeding this dataset into machine‑learning models to design the super‑antigen.

No need for needles

A distinctive feature of the vaccine is its needle‑free delivery: a microfluidic jet injects the antigen directly into the skin via a high‑velocity liquid stream.

This approach enhances global applicability by minimizing required dose volume, eliminating sharps waste, and improving acceptance in contexts where traditional injections are undesirable. Moreover, the formulation exhibits greater thermostability than many mRNA vaccines and does not rely on ultra‑cold storage, facilitating deployment in low‑ and middle‑income regions and during swift outbreak responses.

What are the next steps?

The initial study enrolled a limited cohort and aimed to evaluate safety, tolerability, and immunogenicity. Conducted between December 2021 and September 2023, the trial administered four dose levels to 39 participants, who were generally well tolerated with no significant adverse safety signals reported.

‘The remarkable success of this AI‑engineered super‑antigen trial represents a pivotal advance in our capacity to provide broad, durable viral protection,’ said Professor Marian Knight, Scientific Director of the UK’s National Institute for Health and Care Research (NIHR).

Building on these encouraging outcomes, the team will initiate a Phase 2 clinical trial to evaluate the vaccine’s immunogenicity across a larger, more diverse population and to confirm its capacity to generate robust, broadly protective immunity.

Source link